KEVIN HASEGAWA ENG, PHD

Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center,
Department of Biostatistics & Bioinformatics
Elm and Carlton Streets, Buffalo, NY 14263
+1 (716) 845-1300 x6504
kevin.eng@roswellpark.org

EDUCATION

2011 Ph.D. Statistics. University of Wisconsin-Madison. Madison, Wisconsin.
2009 M.S. Statistics. University of Wisconsin-Madison. Madison, Wisconsin.
2005 Sc.B. Statistics. Honors. Brown University. Providence, Rhode Island.

PROFESSIONAL APPOINTMENTS

2018- Associate Professor of Oncology. *Biostatistics and Bioinformatics*.
Roswell Park Cancer Institute. Buffalo, New York.

2013-2018 Assistant Professor of Oncology. *Biostatistics and Bioinformatics*.
Roswell Park Cancer Institute. Buffalo, New York.

2013- Research Assistant Professor. *Biostatistics*.
State University of New York at Buffalo. Buffalo, New York.

2011-2013 Postdoctoral Trainee. *Computation and Informatics in Biology and Medicine*.
University of Wisconsin-Madison. Madison, Wisconsin.

2011-2012 Postdoctoral Fellow. *Integrating Research Ethics and Scholarship Initiative*.
University of Wisconsin-Madison. Madison, Wisconsin.

2005-2006 Data Analyst. *Department of Epidemiology and Biostatistics*.
Memorial Sloan-Kettering Cancer Center.

AWARDS AND HONORS

2015 K01 Career Development Award in Biomedical Informatics (NLM).
2008 ENAR Distinguished Student Paper Travel Award.
2008 Graduate Mentor Award. Graduate School, University of Wisconsin-Madison.

EXPERIENCE AND MEMBERSHIPS

2014- Member. American Statistical Association.
2016- Member. American Association for Cancer Research (#316652)
2016 DOD/CDMRP Ovarian Cancer Research Program, Study Panel
2016 Selected Participant. AACR Genetic Epidemiology Workshop. Boston, MA.
2015 Selected Participant. AACR Cancer Biostatistics Workshop. Lake Tahoe, CA.

RESEARCH HIGHLIGHTS

- **Eng KH**, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO. Paternal lineage early onset hereditary ovarian cancers: a Familial Ovarian Cancer Registry study. *PLoS Genetics*. 2018 Feb 15;14(2):e1007194. PMID: 29447163.

- **Eng KH**, Seagle BL. Covariate-adjusted restricted mean survival times and curves. *J Clin Oncol.* 2017 Feb;35(4):465-466. PMID: 28129530.
- **Eng KH,** Hanlon BM, Bradley WH, Szender JB. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. *Gynecologic Oncology*. 2015. 139(2): 228-35. PMID:26383827.
- **Eng KH**, Schiller E, Morrell K. On representing the prognostic value of continuous gene expression biomarkers. *Oncotarget*. 2015. 6(34):36308-18. PMID:26486086.
- **Eng KH.** Randomized reverse marker strategy design for prospective biomarker validation. *Statistics in Medicine*. 2014. 33(18): 3089-99. PMID: 24639051.

PEER REVIEWED PUBLICATIONS

(Google Scholar 88 entries, h-index 12; NCBI myBibliography 62 entries; orcid:0000-0001-5636-0812)

Ovarian Cancer (30 entries)

- **Eng KH**, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO. Paternal lineage early onset hereditary ovarian cancers: a Familial Ovarian Cancer Registry study. *PLoS Genetics*. *PLoS Genetics*. 2018 Feb 15;14(2):e1007194. PMID: 29447163.
- Phelan C, Ovarian Cancer Association Consortium. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May;49(5):680-691. 2017 Mar 27. PMID: 28346442.
- **Eng KH**, Morrell K, Starbuck K, Spring-Robinson C, Khan A, Cleason D, Akman L, Zsiros E, Odunsi K, Szender JB. Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecol Oncol. 2017 May 8. (17)30844-2. PMID: 28495239.
- Minlikeeva AN, Ovarian Cancer Association Consortium. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes Control. 2017 May;28(5):469-486. Epub 2017 Mar 14. PMID28293802.
- Szender JB, Papanicolau-Sengos A, **Eng KH**, Miliotto AJ, Lugade AA, Gnjatic S, Matsuzaki J, Morrison CD, Odunsi K. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30726-6. PMID28392127
- Komorowski MP, McGray AR, Kolakowska A, **Eng KH**, Gil M, Opyrchal M, Litwinska B, Nemeth MJ, Odunsi KO, Kozbor D. Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy. *Molecular therapy oncolytics*. 2016; 3:16034. PMID: 28035333.
- Szender JB, Grzankowski K, **Eng KH**, Odunsi K, Frederick PJ. Evaluation of satisfaction with work–life balance among US Gynecologic Oncology fellows: A cross-sectional study. *Gynecologic Oncology Reports*. 2016. 16:17-20. PMID:27331129.
- Cannioto RA, Ovarian Cancer Association Consortium. The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. *International Journal of Gynecological Cancer*. 2017; 27(1):11-16. PMID: 27759594.
- Cannioto RA, Ovarian Cancer Association Consortium. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers & Prevention.* 2016. PMID:27197285.

- Cannioto RA, Ovarian Cancer Association Consortium. Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. *British journal of cancer*. 2016; 115(1):95-101. PMID: 27299959,
- Zhang W, Barger CJ, **Eng KH**, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR. PRAME expression and promoter hypomethylation in epithelial ovarian cancer. *Oncotarget*. 2016. PMID:27322684.
- Hampras SS, Ovarian Cancer Association Consortium. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*. 2016; 7(43):69097-69110. PMID: 27533245
- Sucheston-Campbell LE, Ovarian Cancer Association Consortium. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. *Cancer epidemiology, biomarkers & prevention*. 2016. PMID: 27677730.
- Szender JB, Grzankowski KS, **Eng KH**, Odunsi K, Frederick PJ. Evaluation of satisfaction with work-life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study. *Gynecologic oncology reports*. 2016; 16:17-20. PMID: 27331129.
- Choi J, Ye S, **Eng KH**, Korthauer K, Bradley WH, Rader JS, Kendziorski C. IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. *Statistics in Biosciences*. 2016. In Press.
- Brightwell RM, Grzankowski KS, Lele S, **Eng KH**, Arshad M, Chen H, Odunsi K. The CD47 "don't eat me signal" is highly expressed in human ovarian cancer. *Gynecol Oncol*. 2016 Nov;143(2):393-397. PMID:27569584.
- Szender JB, **Eng KH**, Matsuzaki J, Miliotto A, Gnjatic S, Tsuji T, Odunsi K HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. *Gynecologic Oncology*. 2016. 142(1):58-62. PMID:27103177.
- Seagle BL, **Eng KH**, Yeh JY, Dandapani M, Schiller E, Samuelson R, Odunsi K, Shahabi S. Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. *Scientific Reports*. 2016. 6:21591. PMID:26883286.
- Szender JB, Grzankowski KS, **Eng KH**, Lele SB, Odunsi K, Frederick PJ. Satisfaction with work-life balance among US Gynecologic Oncologists, a cross sectional study. *American Journal of Clinical and Experimental Obstetrics and Gynecology*. 2015. 2(4):166-175. PMID:27088113.
- **Eng KH**, Weir I, Tsuji T, Odunsi K. Immuno-stimulatory/regulatory gene expression patterns in advanced ovarian cancer. *Genes & Cancer*. 2015. 6(9-10): 399-407. PMID: 26622942.
- **Eng KH,** Hanlon BM, Bradley WH, Szender JB. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. *Gynecologic Oncology*. 2015. 139(2): 228-35. PMID:26383827.
- Bradley WH, **Eng KH**, Le M, Mackinnon AC, Kendziorski C, Rader JS. Comparing gene expression data from FFPE and qPCR with snap-frozen and microarrays for modeling outcomes of patients with ovarian carcinoma. *BMC Clinical Pathology*. 2015. 15 (1):17. PMID:26412982.
- Minlikeeva AN, Freudenheim JL, Lo-Ciganic WH, **Eng KH**, Friel G, Diergaarde B, Modugno F, Cannioto R, Gower E, Szender JB, Grzankowski K, Odunsi K, Ness RB, Moysich KB. Use

of common analgesics is not associated with ovarian cancer survival. *Cancer Epidemiology Biomarkers & Prevention*. 2015. 24(8):1291-4. PMID:26063476.

- Kolomeyevskaya N, **Eng KH**, Khan AN, Grzankowski KS, Singel KL, Moysich K, Segal BH. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-alpha and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. *Gynecologic Oncology*. 2015. 138(2):352-7. PMID:26001328.
- Seagle BL, Yang CP, **Eng KH**, Dandapani M, Odunsi-Akanji O, Goldberg GL, Odunsi K, Horwitz SB, Shahabi S. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. *Gynecologic Oncology*. 2015. 138(1): 159-64. PMID:25958320.
- Seagle BL, **Eng KH**, Dandapani M, Yeh JY, Odunsi K, Shahabi S. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. *Oncotarget*. 2015. 6(21):18641-52. PMID:26215675.
- Szender JB, Frederick PJ, **Eng KH**, Akers SN, Lele SB, Odunsi K. Evaluation of the National Surgical Quality Improvement Program Universal Surgical Risk Calculator for a Gynecologic Oncology Service. *International Journal of Gynecological Cancer*. 2015. 25(3): 512-520. PMID:25628106.
- **Eng KH**, Tsuji T. Immunoreactive subset of advanced ovarian cancers is associated with prognosis and differential antigen expression. *PLoS One*. 2014. 9(11):e111586. PMID:24380171.
- **Eng KH**, Ruggeri C. Connecting prognostic ligand receptor signaling loops in advanced ovarian cancer. *PLoS One*. 2014. 9(9): e107193. PMID:25244152.
- Daudi S, **Eng KH**, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, Matsuzaki J, Tsuji T, Groman A, Gnjatic S, Spagnoli G, Lele S, Odunsi K. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. *PLoS One*. 2014. 9(8): e104099. PMID:25101620.

Other Cancer (10 entries)

- Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, **Eng KH**, Ellis L. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017. doi:10.1158/1078-0432.CCR-17-0413. [Epub ahead of print] PubMed PMID: 28899973.
- Mayor PC, **Eng KH**, Singel KL, Abrams SI, Odunsi K, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, Bonilla FA, Buckley RH, Sullivan KE, Ballas ZK, Cunningham-Rundles C, Segal BH. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol. 2017 Jun 9. pii: S0091-6749(17)30925-9. PMID: 28606585.
- Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, Odunsi K, **Eng KH**, He J, Qin M, Gardner M, Galluzzi L, Morrison CD. Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget. 2017; 8(2):3197-3205. PMID: 27911273
- Callahan CL, Wang Y, Marian C, Weng DY, **Eng KH**, Tao MH, Ambrosone CB, Nie J, Trevisan M, Smiraglia D, Edge SB, Shields PG, Freudenheim JL. DNA methylation and

breast tumor clinicopathological features: the Western New York Exposures and Breast Cancer (WEB) Study. *Epigenetics*. 2016. PMID: 27245195.

- Fischer JA, Rossetti S, Datta A, **Eng KH**, Beghini A, Sacchi N. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia. *Molecular Cancer*. 2015. *14*(1), 7. PMID: 25612891.
- Gelman IH, Peresie J, **Eng KH**, Foster BA. Differential requirement for Src-family tyrosine kinases in the initiation, progression and metastasis of prostate cancer. *Molecular Cancer Research*. 2014. 12(10): 1470-9. PMID:25053806.
- Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, **Eng KH**, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS, Trump D. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. *PNAS*. 2014. *111*(6), E672-E681. PMID: 24469795.
- Su B, Gillard B, Gao L, **Eng KH**, Gelman I. Src controls castration-recurrence of CWR22 prostate cancer xenografts. *Cancer Medicine*. 2013. 2(6): 784-792. PMID: 24403252.
- Shen H, Morrison CD, Zhang J, Underwood W 3rd, Yang N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, Wang J, Liu S, Trump DL, Candace JS. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. *Oncotarget*. 2013. *4*(11), 2124-2134. PMID:24231253.
- **Eng KH**, Kvitek D, Keles S, Gasch A. Transient genotype-environment interactions following environmental shock provide a source of expression variation for essential genes. *Genetics*. 2010. 184: 587-593. PMID:19966067.

Statistics Methodology (11 entries)

- **Eng KH**, Seagle BL. Covariate-adjusted restricted mean survival times and curves. *J Clin Oncol.* 2017 Feb;35(4):465-466. PMID: 28129530.
- **Eng KH**, Schiller E, Morrell K. On representing the prognostic value of continuous gene expression biomarkers. *Oncotarget*. 2015. 6(34):36308-18. PMID:26486086.
- Ruggeri C, **Eng KH**. Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models. *Cancer Informatics.* 2015. 13(S7): 67-75. PMID:25657571.
- **Eng KH.** Randomized reverse marker strategy design for prospective biomarker validation. *Statistics in Medicine*. 2014. 33(18): 3089-99. PMID: 24639051.
- **Eng KH**, Hanlon BH. Discrete mixture modeling to address genetic heterogeneity in time-to-event regression. *Bioinformatics*. 2014. 30(12):1690-1679. PMID: 24532723.
- **Eng KH**, Wang S, Bradley WH, Rader JS, Kendziorski C. Pathway-index models for construction of patient-specific risk profiles. *Statistics in Medicine*. 2013. *32*(9), 1524-1535. PMID:23074142.
- Boyd K, **Eng KH**, Page DP. Area under the precision-recall curve: point estimates and confidence intervals. In *Machine Learning and Knowledge Discovery in Databases* (pp. 451-466), 2013. Springer Berlin Heidelberg.
- **Eng KH**, Corrada Bravo H, Keles S. Phylogenetic Mixture Model for the Evolution of Gene Expression Families. *Molecular Biology and Evolution*. 2009. 26(10):2363-2372. PMID: 19602540.

- Corrada Bravo H, Wright S, **Eng KH**, Keles S, Wahba G. Estimating Tree Structured Covariance Matrices via Mixed-Integer Programming. *Journal of Machine Learning Research*. 2009. 5:41-48. PMID: 22081761.
- Begg CB, **Eng KH**, Hummer AJ. Statistical tests for clonality. *Biometrics*. 2007. 63(2): 522-530. PMID:17688504.
- **Eng KH**, Kosorok MR. Sample size formula for the supremum log rank statistic. *Biometrics*. 2005. 61(1):86-91. PMID: 15737081.

PEER REVIEWED ABSTRACTS

- Szender JB, Papanicolau-Sengos A, **Eng KH**, Miliotto AJ, Lugade A, Gnjatic S, Matsuzaki J, Odunsi K. NY-ESO-1 is associated with an aggressive phenotype of ovarian cancer. Gynecologic Oncology. 2017. 145:30.
- Szender JB, Emmons T, Morrell K, Belliotti S, Dickson D, Khan A, Mayor PC, Lele SB, Frederick PJ, Zsiros E, Odunsi K, **Eng KH**, Segal BH. Impact of ascites volume on clinical outcomes in epithelial ovarian cancer. *Gynecologic Oncology*. 2017. 145:79.
- Cleason D, Spring-Robinson CL, Morrell K, Khan A, Akman L, Lele SB, Frederick PJ, Odunsi K, Szender JB, **Eng KH**. The impact of ovarian cancer spread on survival in advanced epithelial ovarian cancer. *Gynecologic Oncology*. 2017. 145:131-132.
- Rosario S, Dalimov Z, Kirk J, Morrell K, **Eng KH**, Ellis L. Increased expression of EZH2 and TOP2A predicts for a poorer prognostic outcome in genitourinary cancers. *Cancer Research* 2016. 76(S2):B10.
- Seagle BL, Hofstteter G, Yang CP, **Eng KH**, Odunsi-Akanji T, Odunsi O, Shahabi S. TP53 hotspot mutations in ovarian cancer: selective resistance to microtubule stabilizing agents in monoclonal cells and comparison of clinical outcomes from the Cancer Genome Atlas. *Cancer Research*. 2015. 75 (S15): 4442.
- Odunsi-Akanji T, Seagle BL, **Eng KH**, Odunsi KO, Shahabi S. Exon-specific p53 mutations drive different models of ovarian cancer risk. *Gynecologic Oncology*. 2015. 137:66-67.
- Grzankowski K, Khan N, Kolomeyevskaya N, Moysich KM, **Eng KH**, Lele SB, Odunsi KO, Segal BH. Serum mitochondrial DNA shows greater effect size than CA-125 in predicting survival in epithelial ovarian cancer. *Gynecologic Oncology*. 2015. 137:13-14.
- Singh S, **Eng KH**, Singh A, Reid M, Malhotra U. Impact of smoking on stage I-III gastric cancer: a single-center retrospective study. *American Journal of Gastroenterology*. 2014. 109: S55-S56.
- Brightwell R, **Eng KH**, Lele SB, Odunsi KO. Duration of intra-chemotherapy anemia is associated with prngosis and survival in epithelial ovarian cancer. *Gynecologic Oncology*. 2014. 134(2): 430.
- Le M, Bradley WH, **Eng KH**, Kendziorski C, Rader JS, Mackinnon A. Development and validation of a qPCR gene expression panel using archived FFPE ovarian carcinoma samples for modeling predictive treatment in serous ovarian carcinoma. *Journal of Molecular Diagnostics*. 2013. 15(6): 909-910.
- Tsuji T, **Eng KH**, Gnjatic S, Matsuzaki J, Brightwell R, Miliotto A, Emerson R, Desmarais C, Lindsley E, Rubinstein J, Wang J, Liu S, Robins H, Odunsi K. Tumor-infiltrating lymphocyte clonality predicts prognosis in human ovarian cancer. *Journal for Immunotherapy in Cancer.* 2013. 1(S1): P64.

- Bradley WH, **Eng KH**, Kendziorski C, Le M, Mackinnon A, Rader JS. Gene expression levels in archived FFPE ovarian carcinoma samples. *Gynecologic Oncology.* 2013. 130(1): e136-137.

RESEARCH GRANTS – ACTIVE

DOD IIRA — Eng (PI) — 4/2018-3/2022
Role: PI, Effort 15%

NIH-NLM K01 Career Award — Eng (PI) — 4/2015-3/2018
Informatic methods for differential signaling and immune co-regulatory expression.
Role: PI, Effort 75%

NYSTEM — Odunsi (PI) — 10/2015-9/2019
Programming hematopoetic stem cells for targeting t-cell therapy in relapsed ovarian cancer patients.
Role: Co-Investigator, Effort 10%

NIH-NCI R01 — Segal/Moyisch — 6/2015-5/2020
Novel Immunological Biomarkers for Ovarian Cancer Prognosis.
Role: Co-Investigator, Effort 5%

NIH-NCI SPORE — Odunsi/Moysich — 9/2013-6/2018
RPCI-UPCI Ovarian Cancer SPORE
Role: Co-investigator, Effort 5%

Roswell Park Alliance Foundation — Eng/Moysich (PI) — 9/2016-12/2018
Familial Ovarian Cancer Update Study.
Role: Co-PI, Effort 30% concurrent with K01

RESEARCH GRANTS - COMPLETED

RPCI-UPCI Spore Career Development Project — Canniotto (PI) — 7/2016-3/2018
Role of Comorbidities and Epidemiologic Factors in Ovarian Cancer Prognosis
Role: Co-Mentor, Effort Donated

RPCI-UPCI Spore Career Development Project — Eng (PI) — 8/2014-6/2016
Genetic characterization of cancer testis antigen rich tumors and their microenvironment.
Role: PI, Effort 30%

Roswell Park Alliance Foundation — Eng (PI) — 9/2013-3/2015
Pilot study of personalized treatment markers in recurrent ovarian cancer.
Role: PI, Effort 30%

Roswell Park Alliance Foundation — Moysich (PI) — 9/2013-8/2014

Development of innate immune responses in tumor microenvironment as a prognostic signature for progression-free survival in women with advanced epithelial ovarian cancer.
Role: Co-investigator, Effort 15%

University of Wisconsin Carbone Cancer Center Kendziorski (PI) 8/2011-7/2012
Validation of a genomic based assay for personalized treatment of recurrent ovarian cancer
Role: Co-investigator, Effort 50%

INVITED TALKS

2016 "X-linked variants in familial ovarian cancer" RPCI Cancer Prevention Grand Rounds.
2014 "Co-stimulatory/regulatory transcripts in ovarian cancer: a study in data mining" RPCI Science Retreat. Geneseo, NY.
2012 "Pathway index models for the construction of patient-specific risk profiles." JSM 2012, San Diego, CA.
2012 "Pathway index models for the construction of patient-specific risk profiles." National NLM Informatics Conference 2012, Madison.
2012 "Statistics and the responsible conduct of research." Dept. of Statistics, Madison.
2008 "Linear mixed effects clustering model for multi-species time course gene expression data." ENAR 2008, Washington DC.

CONFERENCE PRESENTATIONS

2017 "Continuous biomarker strategy characterization by RMS curve" Lifetime Data Analysis 2017. Storrs, CT.
2011 "Derivation of biologically informative and therapeutically relevant expression-based patient-specific risk profiles for ovarian cancer." MSKCC. Systems Biology of Diversity in Cancer. New York.
2010 "Tree structured variation and neutral models." Statistical Genomics in Biomedical Research. Banff, Canada.
2007 "Mixed effects clustering model for multi-species time course gene expression data." Midwestern Symposium on Computational Biology and Bioinformatics. Northwestern University.

INSTITUTIONAL SERVICE

2014 - RPCI-UPCI Ovarian Cancer SPORE member
2013 - IRB-03 (Regular member)
2013 - IRB-01, IRB-02 (Ad hoc member)
2013 - GYN Disease Site Research Group
2013 - Familial Ovarian Cancer Registry, steering committee

Reviewer for Bioinformatics, Biometrics, BMC Cancer, Infection and Immunity, JAMA Oncology, Journal of Ovarian Research, Medical Mycology, Statistical Applications in Genetics and Molecular Biology, PLoS One.

Updated: 3/26/2018